B. Klebanov

发表

Influence of Cationic Lipid Composition on Gene Silencing Properties of Lipid Nanoparticle Formulations of siRNA in Antigen-Presenting Cells

Boris Klebanov, Akin Akinc, A. Akinc, 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

Systemic RNAi-mediated Gene Silencing in Nonhuman Primate and Rodent Myeloid Cells

Daniel G. Anderson, S. Milstein, R. Weissleder, 2012, Molecular therapy. Nucleic acids.

T Lymphocytes + and CD 8 + I . 1 Negatively Regulate Functions of CD 4 and Its Activation-Inducible Short Isoform α Cutting Edge : Hypoxia-Inducible Factor 1

R. Wenger, A. Ohta, M. Sitkovsky, 2006 .

Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice

A. Letai, A. Look, A. Kentsis, 2016, Leukemia.

Selinexor reduces the expression of DNA damage repair proteins and sensitizes cancer cells to DNA damaging agents

Margaret S. Lee, B. Klebanov, W. Senapedis, 2018, Oncotarget.

Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death

A. Azmi, Margaret S. Lee, R. Mohammad, 2016, Oncotarget.

Selinexor, a Selective Inhibitor of Nuclear Export (SINE) Compound, Shows Synergistic Anti-Tumor Activity in Combination with Dexamethasone Characterized By Specific Pattern of Gene Expression in Multiple Myeloma (MM)

Margaret S. Lee, B. Klebanov, Y. Landesman, 2015 .

A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia.

R. Garzon, R. Carlson, M. Andreeff, 2017, Blood.

A method for quantification of exportin-1 (XPO1) occupancy by Selective Inhibitor of Nuclear Export (SINE) compounds

Margaret S. Lee, E. Baloglu, B. Klebanov, 2015, Oncotarget.

The Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Demonstrates Broad and Durable Clinical Activity in Relapsed / Refractory Non Hodgkin’s Lymphoma (NHL)

J. Byrd, I. Flinn, R. Garzon, 2014 .

758OSELINEXOR (KPT-330), AN ORAL, SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) SHOWS ANTI-PROSTATE CANCER (PRCA) ACTIVITY PRECLINICALLY & DISEASE CONTROL IN PATIENTS (PTS) WITH CHEMOTHERAPY REFRACTORY, CASTRATE-RESISTANT PROSTATE CANCER (CRPC).

A. Shields, M. Mirza, B. Klebanov, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Anti Tumor Activity Of Selinexor (KPT-330), A First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) XPO1/CRM1 Antagonist In Patients (pts) With Relapsed / Refractory Multiple Myeloma (MM) Or Waldenstrom’s Macroglobulinemia (WM)

J. Byrd, G. Pond, A. Oza, 2013 .

Preliminary Evidence Of Anti Tumor Activity Of Selinexor (KPT-330) In a Phase I Trial Ofa First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) In Patients (pts) With Relapsed / Refractory Non Hodgkin’s Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

J. Byrd, G. Pond, A. Oza, 2013 .

Phase I Trial of Selinexor (KPT-330), A First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) In Patients (pts) With Advanced Acute Myelogenous Leukemia (AML)

J. Byrd, G. Pond, A. Oza, 2013 .

Degradable Lipid Nanoparticles with Predictable In Vivo siRNA Delivery Activity

Robert Langer, Boris Klebanov, Kathryn A. Whitehead, 2014, Nature Communications.

Synthesis and study of the pharmacologic properties of derivatives of 1,2,3,4-tetrahydro-5-nitropyrimidine

V. Kukhar, B. Klebanov, G. Remennikov, 1991, Pharmaceutical Chemistry Journal.

6-Methyl- and 1,6-dimethyl-4-aryl-5-nitro-2-oxo-1,2,3,4-tetrahydropyrimidines: Modulators of calcium influx

B. Klebanov, G. Remennikov, L. Kurilenko, 1994, Pharmaceutical Chemistry Journal.

New fluorine-containing hypotensive preparations

B. Klebanov, S. Herzig, R. Handrock, 2001 .

HPLC determination of nicorandyl in the rat blood serum

B. Klebanov, O. I. Kal'chenko, M. Lozinskii, 1996, Pharmaceutical Chemistry Journal.

Potassium channel modulators: Chemistry and pharmacology (review)

B. Klebanov, L. M. Yagupol’skii, S. S. Shavaran, 1993, Pharmaceutical Chemistry Journal.

Clinical Dosing Regimen of Selinexor Maintains Normal Immune Homeostasis and T-cell Effector Function in Mice: Implications for Combination with Immunotherapy

B. Klebanov, S. Dougan, Y. Landesman, 2016, Molecular Cancer Therapeutics.

In vivo silencing of the transcription factor IRF5 reprograms the macrophage phenotype and improves infarct healing.

Daniel G. Anderson, P. Libby, R. Weissleder, 2013, Journal of the American College of Cardiology.

Cutting Edge: Hypoxia-Inducible Factor 1α and Its Activation-Inducible Short Isoform I.1 Negatively Regulate Functions of CD4+ and CD8+ T Lymphocytes

R. Wenger, A. Ohta, M. Sitkovsky, 2006, The Journal of Immunology.

Combination of Selinexor and the Proteasome Inhibitor, Bortezomib Shows Synergistic Cytotoxicity in Diffuse Large B-Cells Lymphoma Cells In Vitro and In Vivo

A. Azmi, R. Mohammad, B. Klebanov, 2016 .

Abstract 1299: Selinexor, a selective inhibitor of nuclear export (SINE) compound shows enhanced anti-tumor activity when combined with either venetoclax or bendamustine in diffuse large B cell lymphoma (DLBCL) mouse models

Margaret S. Lee, B. Klebanov, Y. Landesman, 2016 .

Selinexor synergizes with dexamethasone to repress mTORC1 signaling and induce multiple myeloma cell death

Margaret S. Lee, E. Baloglu, B. Klebanov, 2018, Oncotarget.

Primary selection of hypocholesteremic agents

B. Klebanov, 1969, Bulletin of Experimental Biology and Medicine.

Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination with Fludarabine and Cytarabine in Pediatric Patients with Relapsed or Refractory AML

R. Ribeiro, J. Rubnitz, H. Youssoufian, 2015 .

Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis.

B. Klebanov, J. Italiano, K. Machlus, 2017, Blood.

Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds

B. Klebanov, W. Senapedis, Y. Landesman, 2015, BMC Cancer.

Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibody

Changyun Hu, D. Wiederschain, M. Gostissa, 2022, Oncoimmunology.

Abstract 3810: Selinexor (KPT-330), a novel selective inhibitor of nuclear export (SINE), shows single agent efficacy against alveolar soft part sarcoma (ASPS) in vivo

G. Demetri, R. Carlson, E. Baloglu, 2014 .

Machine Elements: Life and Design

David Barlam, Boris Klebanov, Frederic Nystrom, 2007 .

Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds

B. Klebanov, W. Senapedis, Y. Landesman, 2015, BMC Cancer.

Synthesis and antiinflammatory properties of carboxyphenylamides of nicotinic and isonicotinic acid 1-oxides

B. Klebanov, V. A. Portnyagina, T. K. Ryabukha, 1979, Pharmaceutical Chemistry Journal.

EPOXY DERIVATIVES OF N-ARYLSULFONYLBICYCLO2.2.1HEPT-2-EN-EXO-5-YLMETHYLAMINES

B. Klebanov, L. Gorb, A. O. Kas’yan, 1995 .

The Exportin-1 Inhibitor Selinexor Exerts Superior Antitumor Activity when Combined with T-Cell Checkpoint Inhibitors

G. Lesinski, R. Shakya, B. Klebanov, 2017, Molecular Cancer Therapeutics.

Abstract 4532: Preclinical evaluation of JTX-1811, an anti-CCR8 antibody with enhanced ADCC activity, for preferential depletion of tumor-infiltrating regulatory T cells

Changyun Hu, M. Gostissa, E. Stack, 2020, Immunology.

Synthesis and cardiovascuar effects of fluorine-containing arylcyanoguanidines (pinacidil analogs)

B. Klebanov, I. Maletina, M. Lozinskii, 1997, Pharmaceutical Chemistry Journal.